Tennessee Endocrinologist. Seeking a board certified or board eligible Endocrinologist to either join an established, busy clinic or establish independent practice with hospital financial assistance. ...
Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced today that it is reaffirming its plan to submit a new drug application (NDA) for Trizytek TM (liprotamase) in the first-half of 2009. Trizytek is a non-porcine derived enzyme replacement therapy for patients with pancreatic insufficiency.
For decades, scientists have been studying nuclear hormone receptors to gain a better understanding of how they turn genes on and off throughout the body and how they function as key drug targets for a number of diseases, such as diabetes, breast cancer, osteoporosis and high cholesterol. A new UVA Health System study, led by Fraydoon Rastinejad, Ph.D.
Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil demonstrating that its Intravail(R) formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes. The results of the study, presented by Dr.
Diabetes appears to be linked with an increased risk of pelvic girdle syndrome. This is shown in a new study from the Norwegian Institute of Public Health and Akershus University Hospital. The study showed that five percent of women had had serious pelvic girdle syndrome (pain in both iliosacral ligaments and symphysis pubis) during their last pregnancy. Three percent of these women reported that they had diabetes, while diabetes was seen in only 0.
Ambrx Inc. announced Phase I/II clinical trial data demonstrating that ARX201, the company's long-acting human growth hormone (hGH) analogue developed in collaboration with Merck Serono, normalized insulin-like growth factor I (IGF-I) levels while delivering an acceptable safety and tolerability profile in adults with Growth Hormone deficiency.
Scientists have long known that women's preferences for masculine men change throughout their menstrual cycles. A new study from Indiana University's Kinsey Institute is the first to demonstrate differences in brain activity as women considered masculinized and feminized male faces and whether the person was a potential sexual partner.
